Drug Trial Radar · NCT03934307
A Study to Evaluate ALN-AGT01 in Patients With Hypertension
Last checked: Nov 20, 2026Latest source record: Jan 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
124
Actual
Start
May 1, 2019
Primary completion
Apr 20, 2022
Study completion Jan 4, 2023
Sponsor
- Lead sponsor
- Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
- Sponsor type
- Industry
- First posted
- May 1, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of subcutaneous (SC) ALN-AGT01 (zilebesiran) in participants with hypertension. The study will be conducted in 4 parts: Part A will be a single ascending dose (SAD) phase in hypertensive participants, Part B will be a single dose (SD) phase in hypertensive participants with controlled salt intake, Part D will be a MD phase in hypertensive participants who are obese, and Part E will be an open-label SD phase with co-administration of irbesartan in hypertensive patients.
Conditions
- Hypertension
Interventions
ALN-AGT01Drug
ALN-AGT01 will be administered by subcutaneous (SC) injection.
ALN-AGT01-Matching PlaceboDrug
Normal saline (0.9% NaCl) matching volume of ALN-AGT01 doses will be administered SC.
IrbesartanDrug
Irbesartan will be administered orally.
Irbesartan-Matching PlaceboDrug
Irbesartan-matching placebo will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events (AEs)Time frame: Parts A, B and E: each up to approximately 12 months; Part D: up to approximately 18 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Clinical Trial Site
Edinburgh, United Kingdom
Clinical Trial Site
London, United Kingdom
Clinical Trial Site
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.